![Marty J. Duvall](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marty J. Duvall
Directeur/Membre du Conseil chez
INNATE PHARMA
Profil
Marty J.
Duvall currently works at Innate Pharma SA, as Director from 2025.
Mr. Duvall also formerly worked at Tocagen, Inc., as Chief Executive Officer, Oncopeptides AB, as Chief Executive Officer, and Angiex, Inc., as Chief Executive Officer & Director.
Postes actifs de Marty J. Duvall
| Sociétés | Poste | Début |
|---|---|---|
| INNATE PHARMA | Directeur/Membre du Conseil | 22/05/2025 |
Anciens postes connus de Marty J. Duvall
| Sociétés | Poste | Fin |
|---|---|---|
| FORTE BIOSCIENCES, INC. | Directeur Général | - |
| ONCOPEPTIDES AB | Directeur Général | - |
Angiex, Inc.
 Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Develops vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis | Directeur Général | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Develops biopharmaceutical drugs | Health Technology |
Innate Pharma SA
 Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes | Health Technology |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Angiex, Inc.
Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Develops vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis | Commercial Services |
